Osimertinib （AZD9291） decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer...
Osimertinib （AZD9291） decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells
About this item
Full title
Osimertinib （AZD9291） decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells
Author / Creator
Journal title
中国药理学报：英文版, 2017, Vol.38 (11), p.1512-1520
Language
English
Formats
More information
Scope and Contents
Contents
Osimertinib （AZD9291） is a third-generation epidermal growth factor receptor （EGFR） tyrosine kinase inhibitor （TKI） that has been approved for the treatment of EGFR-mutated non-small cell lung cancer （NSCLC）. In NSCLC patients, an EGFR mutation is likely to be correlated with high levels of expression of programmed death ligand-1 （PD-L1）. Here, we...
Alternative Titles
Full title
Osimertinib （AZD9291） decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_chongqing_primary_673835639
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_chongqing_primary_673835639
Other Identifiers
ISSN
1671-4083
E-ISSN
1745-7254
How to access this item
Log in as a Library member
